FIELD: biotechnology.
SUBSTANCE: invention can be used in medicine to induce anti-tumour immunity against expression of Lck, WHSC2, SART2, SART3, UBE2V, EGFR, PTHrP or MRP3 cancer. A peptide is obtained from 4 CTL epitopes of cancer antigens linked through amino acid linkers. The resulting peptide is used to stimulate peripheral blood lymphocytes to obtain a combination of CTL specific for the cancer antigen.
EFFECT: invention allows to obtain a peptide vaccine for cancer treatment in a wide range of patients without the necessity of HLA-typing and regardless of the HLA types in patients.
11 cl, 17 dwg, 4 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| EMULSIFIER COMPOSITION AND USE THEREOF | 2019 |
|
RU2793862C2 |
| ANTITUMOR AGENT AND A METHOD OF ITS EVALUATION | 2019 |
|
RU2803148C2 |
| NOVEL PEPTIDE WITH 5 LINKED CTL EPITOPES | 2014 |
|
RU2627175C2 |
| FELAMENTOUS FUNGI CELL WITH PROTEASE DEFICIT AND METHODS OF ITS APPLICATION | 2013 |
|
RU2645252C2 |
| METHOD FOR ENZYMATIC REMOVAL OF BIOFILM, COMPOSITION AND SET | 2008 |
|
RU2495098C2 |
| Bcl-2 PROTEINS, FRAGMENTS THEREOF, AND APPLICATION THEREOF IN PATIENTS WITH MALIGNANT TUMOUR | 2004 |
|
RU2367468C2 |
| HJURP PEPTIDES AND VACCINES CONTAINING THEM | 2011 |
|
RU2570560C2 |
| PEPTIDE CANCER VACCINES EXPRESSING TUMOUR-SPECIFIC ANTIGENS | 2008 |
|
RU2464275C2 |
| TEM8 PEPTIDES AND VACCINES CONTAINING THEM | 2008 |
|
RU2498993C2 |
| TTK PEPTIDES AND VACCINES CONTAINING THEM | 2010 |
|
RU2531348C2 |
